Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

February 20, 2025

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
February 4, 2025

Immunic to Participate in Investor and Scientific Conferences in February
January 7, 2025

Immunic Highlights 2024 Accomplishments and Upcoming Milestones
November 26, 2024

Immunic, Inc. to Participate in Investor Conference in December
November 13, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Show per page